CD274 and non-small cell lung carcinoma: Recently, prospective trials in patients with untreated NSCLC with brain metastases have noted that pembrolizumab results in a 29.7% response rate in patients with tumors with a programmed death-ligand 1 (PD-L1) of greater than or equal to 1%33 and that the combination of atezolizumab, carboplatin, and pemetrexed for NS-NSCLC resulted in a median intracranial progression-free survival of 6.9 months, an intracranial progression-free survival of 10.4% at 18 months, and similar objective response rates intracranially and extracranially of 40.0% and 47.5%, respectively.34